Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. ACN
3. IBM
4. MU
5. DPZ
6. NVDA
7. PRIM
8. META
9. SPY
10. SPCX

Go back to Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
(NASDAQ: LTRN) Delayed: 3.86 -0.02 (0.52%)
Previous Close $3.88    52 Week High $ 
Open $3.76    52 Week Low $ 
Day High $3.87    P/E N/A 
Day Low $3.76    EPS $ 
Volume 13,094